Lifestyle Asset Management Inc. Cuts Stock Position in Eli Lilly and Company (NYSE:LLY)

Lifestyle Asset Management Inc. trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 12.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 388 shares of the company’s stock after selling 54 shares during the quarter. Lifestyle Asset Management Inc.’s holdings in Eli Lilly and Company were worth $302,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Lipe & Dalton purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $26,000. Tidemark LLC acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $29,000. Core Wealth Advisors Inc. lifted its stake in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares during the last quarter. Frank Rimerman Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $37,000. Finally, St. Johns Investment Management Company LLC raised its holdings in shares of Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after purchasing an additional 37 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the sale, the insider now owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The disclosure for this sale can be found here. Insiders have sold 858,742 shares of company stock valued at $735,573,781 over the last quarter. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY traded down $8.61 during trading on Wednesday, hitting $898.10. The stock had a trading volume of 3,076,361 shares, compared to its average volume of 2,948,155. The firm has a market capitalization of $853.56 billion, a P/E ratio of 132.27, a PEG ratio of 1.97 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $918.50. The company’s 50-day moving average price is $821.29 and its 200 day moving average price is $745.62.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the business posted $1.62 earnings per share. The business’s revenue was up 26.0% compared to the same quarter last year. On average, equities research analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Argus increased their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup increased their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. The Goldman Sachs Group boosted their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,001.00 target price on shares of Eli Lilly and Company in a research report on Wednesday. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $812.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.